Senseonics Holdings Inc SENS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Senseonics To Participate in Upcoming Institutional Investor Conferences
Senseonic Shares Slide on Underwritten Offering Price
Trading Information
- Previous Close Price
- $7.99
- Day Range
- $7.83–8.65
- 52-Week Range
- $4.79–10.64
- Bid/Ask
- $8.57 / $8.64
- Shares Outstanding
- 52.87M
- Market Cap
- $454.19M
- Volume/Avg
- 867,663 / 727,812
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 130
- Website
- https://www.senseonics.com
Valuation
Metric | SENS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.03 |
Price/Sales | 8.59 |
Price/Cash Flow | — |
Price/Earnings
SENS
Financial Strength
Metric | SENS |
|---|---|
Quick Ratio | 6.22 |
Current Ratio | 6.74 |
Interest Coverage | −21.00 |
Quick Ratio
SENS
Profitability
Metric | SENS |
|---|---|
Return on Assets (Normalized) | −70.48% |
Return on Equity (Normalized) | −136.83% |
Return on Invested Capital (Normalized) | −82.82% |
Return on Assets
SENS
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|$G?zMD | LOCK|#%Gq | $190B | |||
| Medtronic PLC MDT | LOCK|<kTZp>$ | LOCK|!d$Fn | $130B | |||
| Stryker Corp SYK | LOCK|yyb@#SK | LOCK|hb | $124B | |||
| Boston Scientific Corp BSX | LOCK|?@?z<G | LOCK|fPz# | $62B | |||
| Edwards Lifesciences Corp EW | LOCK|?#^&w<! | LOCK|SwVS | $59B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|m?H?#^& | LOCK|#>& | $37B | |||
| Koninklijke Philips NV ADR PHG | LOCK|zPz | LOCK|F<l | $30B | |||
| DexCom Inc DXCM | LOCK|&z!?!?! | LOCK|b<N!% | $30B | |||
| Steris PLC STE | LOCK|FqmqS$ | LOCK|@&sV# | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|$^@TVj#L | LOCK|wZ | $20B |
United States